EP0303516A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Topically active compositions of double-stranded RNAs
Assignee: HEM Pharmaceuticals Corp
•
Filing: 1988-08-12
•
Granted: —
•
Expires: 2008-08-12
Abstract
Abstract Surfactant-stabilized ternary complexes of dsRNAs in topical pharmaceutical compositions, optionally also including a lymphokine and/or an inhibitor of reverse transcriptase, are applied topically to the affected or exposed area to treat or prevent viral infections, such as herpes virus, and other infectious conditions, particularly venereally transmitted pathogens. Ternary complexes of two strands of complementary RNA plus a compatible surfactant stabilized against temperature-associated enzymatic inactivation are described.
Inventors
- 👤 William A Carter
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 13:52
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7088; A61K31/713; A61K31/74; A61K31/765; A61K47/00; A61K9/00; A61K9/10; A61K9/107; A61K9/1075; A61P; A61P31/00; A61P31/12; C; C07; C07H; C07H21/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
44 words
A pharmaceutical composition for the treatment of a condition susceptible to/sensitive to treatment with mismatched dsRNA comprising in a pharmaceutically acceptable topical carrier, an effective quantity of a mismatched dsRNA in a ternary complex of two mismatched strands of RNA complexed with a surfactant.
Claim 2
Dependent Claim
44 words
A pharmaceutical composition for the treatment of a condition susceptible to/sensitive to treatment with mismatched dsRNA comprising in a pharmaceutically acceptable topical carrier, an effective quantity of a mismatched dsRNA in a ternary complex of two mismatched strands of RNA complexed with a surfactant.
Claim 3
Dependent Claim
24 words
The pharmaceutical composition of claim 1 in which the ternary complex is a micelle in which the mismatched dsRNA is surrounded by the surfactant.
Claim 4
Dependent Claim
39 words
A spermicidal and antivirally-active topical pharmaceutical composition comprising a spermicidally effective amount of a spermicide and from 0.001 to 10 weight percent of a mismatched dsRNA calculated on the total weight of the composition in a pharmaceutically acceptable carrier.
Claim 5
Dependent Claim
39 words
A spermicidal and antivirally-active topical pharmaceutical composition comprising a spermicidally effective amount of a spermicide and from 0.001 to 10 weight percent of a mismatched dsRNA calculated on the total weight of the composition in a pharmaceutically acceptable carrier.
Claim 6
Dependent Claim
20 words
The spermicidal and antivirally-active topical pharmaceutical composition of claim 3, further including a lubricant non-irritating to the human genito-urinary tract.
Claim 7
Dependent Claim
12 words
A condom coated with the pharmaceutical composition of claim 3 or 4.
Claim 8
Dependent Claim
38 words
The composition of claim 1 in which the amount of dsRNA is about 0.001 to 10 weight percent of the overall composition and the amount of surfactant is from 0.005 to 20% by weight of said overall composition.
Claim 9
Dependent Claim
30 words
The composition of claim 1, in which the mismatched dsRNA is a complex of polyinosinate and polycytidylate containing from 1 in 5 to 1 in 30 uracil or guanadine bases.
Claim 10
Dependent Claim
29 words
The composition of claim 1, in which the dsRNA contains regions of bond breakage and the dsRNA exhibits the favourable therapeutic ratio property of rI n ·r(C₁₁₋₁₄,U) n .
Claim 11
Dependent Claim
15 words
The composition of claim 1, in which the dsRNA is rI n ·r(C₁₁₋₁₄,U) n .
Claim 12
Dependent Claim
19 words
The pharmaceutical composition of claim 1 for use in the treatment of viral-affected skin, eye or mucous membrane tissue.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.